UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting

Two studies assessed the bioequivalence and effectiveness of zilucoplan auto-injector (ZLP-AI) administration compared with pre-filled syringe (ZLP-PFS)

Apr. 13, 2026 at 12:20pm

Got story updates? Submit your updates here. ›

A minimalist illustration in glowing neon lines depicting the outline of a medical syringe or auto-injector device, conveying the clinical and technological advancements in rare disease therapies.Innovative medical devices designed to improve treatment options and quality of life for patients living with rare neurological conditions.Smyrna Today

UCB will present additional studies and data analyses highlighting UCB's ongoing commitment to improving outcomes for people living with gMG. Two studies assessed the bioequivalence and effectiveness of zilucoplan auto-injector (ZLP-AI) administration compared with pre-filled syringe (ZLP-PFS). UCB is presenting 21 abstracts in total from its innovative neurology portfolio including 14 epilepsy abstracts and six myasthenia gravis (MG) abstracts at AAN 2026.

Why it matters

While symptom control is essential, successfully treating gMG should go beyond symptom management and consider tailored therapies that align with a patient's needs, lifestyle and quality-of-life goals. UCB's approach to rare disease goes beyond developing effective medicines; it's about improving overall experience and outcome for patients.

The details

DV0013 was a Phase 3b open-label, multicenter study in adult patients with gMG self-administering zilucoplan via auto-injector once daily. DV0012 was a Phase 1, open-label, single-center, two-period crossover study in healthy adult volunteers to establish bioequivalence of zilucoplan delivered via an auto-injector pen compared with a pre-filled syringe.

  • The studies were presented at the 2026 American Academy of Neurology (AAN) meeting.

The players

Omar Sinno, MD

US Medical Strategy Lead, US Rare Disease at UCB.

Kimberly Moran, PhD

SVP & Head, US Rare Disease at UCB.

UCB

A global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Got photos? Submit your photos here. ›

The takeaway

UCB's ongoing commitment to improving outcomes for people living with gMG includes developing innovative solutions designed around patient needs and preferences, such as the auto-injector administration option for the treatment of gMG.